Clinical Trial Update: Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) [Phase 2]

View source ↗

Summary

Phase 2 study of a broad-spectrum HPV vaccine (V505-001) in women aged 16-26 has completed; the trial evaluated the vaccine's potential to prevent HPV infection…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Genital Warts
• Human Papillomavirus Infection
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• V505-001 Broad Spectrum HPV Vaccine

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cervical Cancer, Vulvar Cancer | Phase 2 | Status: COMPLETED